Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …

This COVID‐19 outpatient randomized controlled trials (RCTs) systematic review compares
hospitalization outcomes amongst four treatment classes over pandemic period, geography …

Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …

Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been
elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 …

Gene expression is subject to random perturbations that lead to fluctuations in the rate of
protein production. As a consequence, for any given protein, genetically identical organisms …

Abstract Introduction The Australian National COVID‐19 Clinical Evidence Taskforce was
established in March 2020 to maintain up‐to‐date recommendations for the treatment of …

Brief summary In early symptomatic COVID-19 treatment, high dose oral favipiravir did not
accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro …

Background During pandemics, early outpatient treatments reduce the health system
burden. Randomized controlled trials (RCTs) in COVID-19 outpatients have tested …

Chronic human norovirus (HuNoV) infections in immunocompromised patients result in
severe disease, yet approved antivirals are lacking. RNA-dependent RNA polymerase …

Neurotropic viruses severely damage the central nervous system (CNS) and human health.
Common neurotropic viruses include rabies virus (RABV), Zika virus, and poliovirus. When …